|
|
||||||||
INFLAMMATION/IMMUNITY/MEDIATORS
Departments of 1Medicine B and 2General Surgery, University of Münster, Münster, Germany
Submitted 3 April 2007 ; accepted in final form 17 October 2007
| ABSTRACT |
|---|
|
|
|---|
, IFN-
, IL-1β) and microbial antigens [LPS, lipoteichoic acid, peptidoglycan, CpG-DNA, flagellin, poly(I:C)]. Expression of IL-12 family members and of Toll-like receptor (TLR)3 in HIMEC was assessed by real-time RT-PCR, immunostaining, flow cytometry, and immunoblot analysis. HIMEC display an induction of Epstein-Barr virus-induced gene 3 (EBI3), IL-12p35, and IL-23p19, whereas no expression of IL-12p40 and IL-27p28 was detectable. The strongest induction was induced by proinflammatory factors known to utilize the NF-
B pathway, and expression of EBI3 and IL-23p19 was diminished by an NF-
B inhibitor. HIMEC display regulated expression of TLR3. Adhesion and transmigration assays showed proinflammatory responses after HIMEC stimulation. HIMEC are capable of producing IL-12 family members as a response to microbial stimuli. The TLR3 agonist, poly(I:C), was shown to enhance leukocyte adhesion in vitro in HIMEC. Our data suggest that the intestinal microvasculature is responsive to ligands of TLR3 expressed on intestinal endothelial cells, thereby adding to the regulation of adaptive immunity and leukocyte recruitment.
Epstein-Barr virus-induced gene 3; inflammatory bowel disease; Toll-like receptor 3
CD is widely regarded as a granulomatous Th1-mediated immune disease. Likewise, high mucosal expression levels of IL-12 (29) and EBI3 (26) have been observed in active CD. In addition, a high expression of the IL-12-related cytokine, IL-27, has been observed in granulomatous Th1-mediated diseases, such as sarcoidosis and CD (17).
Intestinal microvascular endothelial cells have recently been recognized as a cell population actively involved in the pathogenesis of inflammatory bowel diseases (IBD) and IBD-associated microvascular dysfunction (13). Mucosal microvascular endothelial cells, which constitute the final anatomical barrier between the blood circulation and subepithelial mucosal compartments, were shown to function as major histocompatibility complex (MHC) class II antigen-presenting cells in vitro (12). In addition, activated monocytes (35) and dendritic cells (38, 39), which are both key antigen-presenting cells in the pathogenesis of IBD, are known to produce IL-12-related molecules in response to microbial antigens.
Both disruption of the intestinal epithelial barrier and subsequent mucosal translocation of enteric microbial antigens (32) are considered major pathophysiological events in the initiation and chronic perpetuation of CD (36) and ulcerative colitis (UC) (34).
Microbial antigens, including LPS and flagellin from flagellated Enterobacteriaceae spp., were shown to elicit rapid innate immune responses, including upregulation of endothelial leukocyte adhesion molecules and enhanced in vitro transendothelial leukocyte migration, in human intestinal microvascular endothelial cells (HIMEC) (21, 25). Furthermore, initial gene array analyses were conducted in our laboratory to characterize the proinflammatory response patterns in primary cultures of HIMEC. Using this assay, we were able to document a marked upregulation of EBI3, compared with the reference microvascular endothelial cell line derived from human skin, HMEC-1. For these reasons, we set about characterizing how specific microbial antigens would induce IL-12-related molecules in primary cultures of HIMEC.
| MATERIAL AND METHODS |
|---|
|
|
|---|
Unless otherwise indicated, all chemicals were obtained from Sigma Aldrich (Steinheim, Germany). The monoclonal EBI3 mAb (clone 2H4G6) was a kind gift by O. Devergne, University of Paris, France. Polyclonal goat anti-human Toll-like receptor (TLR)3 antibody was purchased from R&D Systems. Polyclonal rabbit-anti IL-12p35 was obtained from Santa Cruz Biotechnologies (Santa Cruz, CA).
Gene array analysis.
Intestinal (HIMEC) and dermal microvascular endothelial cells (HMEC-1) were stimulated with recombinant human TNF-
(20 ng/ml) for 4 h and 24 h, respectively. Endothelial cell monolayers were briefly rinsed with PBS and subjected to total RNA extraction as indicated above. Total RNA was quantitated and checked for purity by photometry (BioPhotometer; Eppendorf, Hamburg, Germany). RNA was purified from buffer salt remnants and small molecular contaminants by use of the QIAquick Nucleotide Removal Kit (Qiagen, Hilden, Germany). After reverse transcription, second-strand synthesis and in vitro transcription, biotinylated RNA fragments were hybridized for 16 h onto HG-U133A gene chips (Affymetrix) according to the manufacturer's protocol. Data obtained were processed by using the MicroArraySuite software, version 5.0 (Affymetrix). Expression level changes threefold from baseline were considered significant, whereas lesser values were excluded from further analysis. Sample number was n = 3 for each condition.
Reverse transcription-polymerase chain reaction (RT-PCR).
Endothelial cells were stimulated for 8 h with TNF-
(20 ng/ml), IFN-
(40 ng/ml), LPS from E. coli O111:B4 (1 µg/ml), IL-1β (20 ng/ml), or combined TNF-
/LPS. Control cells remained without any stimulation. In some experiments, the NF-
B inhibitor MG132 was added to the monolayers 30 min before proinflammatory stimulation. Total cellular RNA was extracted from endothelial cells using an acid guanidinium-phenol-chloroform method (TRIzol Reagent; GIBCO-BRL Life Technologies, Grand Island, NY) and treated with ribonuclease-free deoxyribonuclease (Stratagene, La Jolla, CA). Reverse transcription and PCR were performed as described before. Primers and PCR conditions were used as described earlier (20). Experiments were performed three times, and representative results are shown.
Real-time RT-PCR.
Real-time PCR was performed using an ABI Prism 5700 Sequence Detection System (PE Applied Biosystems, Foster City, CA). Each reaction contained 25 µl of 2x SYBR Green Master Mix (comprising 200 nM dATP, dGTP, and dCTP; 400 nM dUTP; 2 mM MgCl2, 0.25 units uracil N-glycosylase, and 0.625 units Amplitaq Gold DNA polymerase), 25 pmol each of sense and antisense primers, and 2 µl of cDNA in a final volume of 50 µl. Amplification of the expected single products was confirmed on 1% agarose gels stained with ethidium bromide. Data analysis used sequence-detection system software provided by the manufacturer where change in fluorescence signal (
Rn) was calculated by the equation
Rn = (Rn+) – (Rn–) with Rn+ being the fluorescence signal of the product and Rn– the fluorescence signal of the baseline emission, where Rn is the normalized reporter, the fluorescence emission intensity of the reporter dye divided by the fluorescence emission intensity of the passive reference dye. The threshold cycle (CT) is the cycle number at which the
Rn crosses threshold. Fold changes in target mRNA expression were determined as fold change = 2
, where
![]() |
Indirect immunofluorescence. For immunohistochemistry, resected specimens of normal colon were fixed in 4% wt/vol paraformaldehyde in PBS, saturated in 20% wt/vol sucrose in PBS overnight, embedded in optimal cutting temperature compound (Sakura, Japan), and snap frozen in isopentane-liquid nitrogen. Sections 5 µm in thickness were prepared, rehydrated in PBS, and blocked in blocking buffer (PBS containing 10% vol/vol of donkey serum) for 1 h at room temperature. Tissue samples were then incubated with the respective antibody (concentrations: 1:1,000 for rabbit anti-human IL-12p35; 14 µg/ml for anti-EBI3 mAb) in blocking buffer for 16 h at 4°C in a humid chamber. Sections were washed 3 x 5 min in PBS, and immunodetection was performed using polyclonal Cy3-labeled donkey anti-rabbit (IL-12p35 and ICAM-1) or anti-mouse (EBI3) antibodies (Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature in the dark. Sections were washed and nuclei were counterstained with 4',6'-diamidino-2-phenylindole (DAPI; Hoechst, Frankfurt, Germany).
For immunocytochemistry, HIMEC were seeded on collagen-coated glass chamber slides (LabTek; Nalgen Nunc International, Naperville, IL), cultured to subconfluence in growth medium, and stimulated as indicated in RESULTS. After brief fixation with 4% wt/vol paraformaldehyde in PBS, cells were washed with PBS, permeabilized with Triton X-100 (0.1% vol/vol in PBS) for 5 min, and blocked in blocking buffer for 1 h at room temperature. Endothelial cells were incubated with the respective primary Ab diluted in blocking buffer at 4°C overnight. After extensive washing with PBS, immunodetection and counterstaining of nuclei were performed as described above. Staining experiments were repeated at least three times, and representative results were shown.
Flow cytometry.
HIMEC monolayers were stimulated with TNF-
(20 ng/ml) or polyinosinic-polycytidylic acid [poly(I:C); 100 µg/ml] for 24 h as indicated. Cells were washed and detached from the cell culture dishes using ice-cold PBS containing 10 mmol EDTA (pH = 8.0) as a cation chelator. After centrifugation, cells were resuspended and permeabilized in FACS buffer (PBS containing 3% vol/vol fetal calf serum, 0.1% wt/vol sodium azide, and 0.1% wt/vol saponin) on ice. Cells were then incubated at 4°C for 1 h with the polyclonal TLR3 antibody. After washing, immunodetection of bound antibody was achieved by incubation with a biotinylated secondary antibody (Pharmingen) and streptavidin-horseradish peroxidase (Pharmingen). Signals were analyzed on a FACSCalibur cytometer (Becton Dickinson, Mountain View, CA) using CellQuest and WinMDI (version 2.8) software. Experiments were performed three times, and representative results are shown.
Immunoblotting. Stimulated HIMEC monolayers were lysed in modified RIPA buffer (50 mM Tris·HCl, pH 7.6, 1 mM EDTA, 150 mM NaCl, 0.25% wt/vol sodium deoxycholate, 1% vol/vol Igepal CA-630, 0.1% wt/vol SDS; all Sigma Chemical, St. Louis, MO) containing Protease Inhibitor Cocktail III (Calbiochem, San Diego, CA) on ice. Lysates were cleared by centrifugation, and total protein concentration was determined by Bradford assay (Bio-Rad, Hercules, CA). Thirty micrograms of total cellular protein were size separated on a 4–20% gradient SDS-PAGE gel (NOVEX, Invitrogen) blotted onto nitrocellulose membranes (Amersham Pharmacia Biotech, Arlington Heights, IL) and blocked in PBS containing 0.1% vol/vol Tween-20, 10% wt/vol nonfat dry milk, and 1% wt/vol BSA. Blots were incubated with EBI3 mAb overnight at 4°C. Immunodetection was performed using horseradish peroxidase-conjugated rabbit anti-mouse antibody (Sigma) and enhanced chemiluminescence reagents (ECL, Amersham Pharmacia Biotech). Blots were stripped and reprobed by use of mouse anti-actin monoclonal antibody (Sigma) followed by the appropriate secondary reagents. Bands were analyzed via NIH imager software, and signal intensities were compared with β-actin of the respective sample. Experiments were performed three times, and representative results are shown.
Leukocyte adhesion and transmigration assays.
Static leukocyte adhesion assays were performed using HIMEC monolayers growing on 96-well plates. HIMEC were stimulated with TNF-
(20 ng/ml) or poly(I:C) at doses ranging from 1 to 100 µg/ml for 24 h. U937 cells were suspended in RPMI 1640 medium containing 10% vol/vol of FBS and 1% wt/vol of glutamine and fluorescence-labeled with calcein AM (Molecular Probes, Eugene, OR) at 37°C for 30 min. Labeled cells (2 x 106 cells/ml) were added on top of the stimulated HIMEC and were allowed to adhere for 20 min at 37°C. The cell culture plates were then briefly rinsed with PBS and centrifuged upside down (5 min, 500 g) to remove any nonadherent U937 cells. Fluorescence was quantified by using the FLUOstar OPTIMA (BMG Labtech, Offenburg, Germany) fluorometer with an excitation wavelength of 485 nm and an emission wavelength of 535 nm. A standard curve was determined by using known numbers of fluorescence-labeled cells.
Endothelial transmigration assays were performed as described earlier (21). In brief, HIMEC were plated onto collagen-coated Transwell polycarbonate filter inserts (24-well format, pore size 5 µm) in growth medium and allowed to grow to confluence. Monolayer integrity was assessed in parallel inserts by crystal violet staining followed by light microscopy. Forty-eight hours after reaching confluence, endothelial monolayers were stimulated with growth medium containing poly(I:C) at differing concentrations or TNF-
as a positive control. U937 cells were labeled with calcein AM as described above. For each well, 4 x 106 labeled U937 cells/ml were added on top of the endothelial monolayers. U937 cells were allowed to migrate for 4 h at 37°C/5% vol/vol CO2, and transmigrated cells (lower well) and cells remaining in the upper well were quantified by fluorescence reading as described above. Equal volumes and counting intervals were applied. Each condition was assessed in triplicate.
Statistical analysis. Values are expressed as means ± SE. The data were analyzed by one-way ANOVA followed by Dunnett's post hoc test for equal sample sizes (SigmaStat v. 3.5, Systat Software, San Jose, CA). P values <0.05 were considered significant. All experiments were performed at least three times.
| RESULTS |
|---|
|
|
|---|
(20 ng/ml, 4 h and 24 h), a prototypical cytokine involved in the pathogenesis of IBD. In contrast, TNF-
stimulation did not lead to any significant upregulation, defined as more than threefold induction of EBI3 gene expression in the reference cell line, HMEC-1 (Table 1).
|
appears to be a potent stimulus for the induction of EBI3 expression in HIMEC, we aimed to determine how other IL-12-related molecules are regulated in HIMEC and HMEC-1 after proinflammatory stimulation. Using an array of established proinflammatory stimuli, including TNF-
(20 ng/ml), IFN-
(40 ng/ml), LPS from E. coli (1 µg/ml), IL-1β (20 ng/ml), or combined TNF-
/LPS for 8 h, we assessed the expression of IL-12p35, EBI3, p19, p28, and IL-12p40 mRNA by semiquantitative RT-PCR. Control cells remained without any stimulation, and PBMC from a healthy donor stimulated with TNF-
/concanavalin A served as a positive control (not shown). Using this assay, a robust induction of EBI3, IL-12p35, and IL-23p19 was detected in HIMEC after stimulation with agents activating the NF-
B pathway (LPS and IL-1β). TNF-
was less effective on the expression of IL-12p35. In contrast, HIMEC did not respond to a high concentration of IFN-
(40 ng/ml), suggesting that the expression of IL-12-related molecules is less likely dependent on activation of the IFN-associated signaling pathways, which include signal transducer and activator of transcription (STAT) and Janus kinase (JAK) (Fig. 1). Of note, no mRNA transcripts for IL-12p40 and IL-27p28 were detectable in HIMEC. This is consistent with a prior report that indicated that endothelial expression of IL-12p40 appears to be dependent on CD154 (CD40 ligand) stimulation, because sole stimulation with TNF-
was not sufficient to induce IL-12p40 mRNA (18). In the dermal reference endothelial cell line (HMEC-1), IL-12p35 and EBI3 were expressed at constitutively high levels, and only minimal regulation occurred in the expression of EBI3 after stimulation with IL-1β and LPS. IL-23p19 was not expressed constitutively, but induction occurred after stimulation with LPS, but not IL-1β, IFN-
, and TNF-
. As observed in HIMEC, both IL-12p40 and IL-27p28 were neither inducible nor expressed at constitutive levels (not shown).
|
B dependent.
Having detected a marked upregulation of specific IL-12-related molecules, we were interested in how intestinal endothelial cells would regulate the expression of these gene products. To a large extent, the biological action of TNF-
is dependent on activation of the transcription factor NF-
B. Using an inhibitor of NF-
B activation, MG132, the expression of the IL-12-related molecules EBI3 and IL23p19 induced by TNF-
(20 ng/ml, 8 h) in HIMEC was diminished, as shown by RT-PCR (Fig. 2). This effect is attributable to MG-132, because the solvent control (DMSO+TNF-
) was not effective as an inhibitor. However, the expression of IL-12p35 appeared to be enhanced after pretreatment with MG132, and TNF-
was again not effective im upregulating IL-12p35 in HIMEC.
|
and LPS, we sought to characterize how other TLR-specific microbial ligands would induce the expression of EBI3. Using HIMEC and a variety of established TLR agents at validated concentrations, we found that EBI3 mRNA was effectively regulated by stimulation with the TLR3 ligand, poly(I:C), in a dose-dependent fashion, as depicted according to real-time RT-PCR data (Fig. 3). In strong contrast, ligands for the TLR heterodimers 1/2 (peptidoglycan) and 2/6 (lipoteichoic acid), and the homodimer TLR9 (bacterial CpG-DNA; ODN2006), all used at established concentrations, were not effective in enhancing the expression of EBI3 mRNA after 16 h of stimulation. As expected from previous studies indicating endothelial expression of TLR4 and TLR5, both LPS from E. coli (TLR4 ligand) and flagellin from Salmonella typhimurium (TLR5 ligand) stimulated EBI3 expression to some extent (Fig. 3).
|
appeared to be a more potent induction stimulus than IL-1β or LPS (Fig. 4A). Notably, stimulation with the TLR3 agonist poly(I:C), as well as with TNF-
, was effective in upregulating TLR3 immunofluorescence in HIMEC, as shown by flow cytometry analysis (Fig. 4B). Finally, high-magnification immunofluorescence staining revealed perinuclear upregulation of TLR3 in permeabilized HIMEC after stimulation with poly(I:C) (100 µg/ml, 16 h) (Fig. 4C).
|
|
(20 ng/ml) or poly(I:C) (100 µg/ml) for 16 h or were left untreated. Permeabilized and fixed cells were then stained with monoclonal EBI3 or IL-12p35 pAb, respectively. Appropriate Cy3-labeled secondary antibodies were used to visualize bound primary Abs. In unstimulated cells, EBI3-specific immunofluorescence was mainly located in the perinuclear cytosol. After proinflammatory stimulation with poly(I:C), cytosolic EBI3-specific immunofluorescence was slightly upregulated. TNF-
stimulation appeared to slightly increase immunofluorescence of IL-12p35, compared with poly(I:C) (arrows), whereas the negative control was lacking any specific immunoreactivity (Fig. 6).
|
|
|
enhanced transendothelial leukocyte migration, as shown by comparative quantification of transmigrated cells and cells remaining in the upper compartment of the transmigration well (Fig. 9B). Poly(I:C) stimulation led to an observable increase in transmigrated cells, but statistical significance was not reached. These findings indicate that stimulation with a TLR3 agonist potentially activates intestinal endothelial cells to induce proinflammatory tissue infiltration. Concordant with this hypothesis, stimulation with poly(I:C) (100 µg/ml, 16 h) strongly upregulated expression of the endothelial leukocyte adhesion molecules, ICAM-1 and VCAM-1, as assessed by RT-PCR (Fig. 9C). Both of these molecules are indicators of proinflammatory endothelial cell activation.
|
| DISCUSSION |
|---|
|
|
|---|
TLRs are members of a large family of genetically conserved pattern-recognition receptors, which are readily activated upon ligation of specific microbial ligands. The human TLR family is comprised of 10 members, all of which are expressed by antigen-presenting cells at constitutive amounts. TLRs were shown to sense and respond to specific pathogen-associated molecular patterns (PAMPs).
Intestinal mucosal microvascular endothelial cells have been recognized as an important anatomical barrier, protecting against invading bacteria and enterotoxins (2), preventing systemic inflammatory responses, as others have shown for the pathogenesis of hemolytic-uremic syndrome (4, 15).
As demonstrated in previous projects, human intestinal microvascular endothelial cells express functional TLRs 4 and 5 (21, 25), which both have to be considered as TLRs of central relevance to the enteric microflora (1). The major ligand of TLR4 was shown to be LPS from gram-negative bacteria, including E. coli, whereas flagellin, an antigen derived from flagellated bacteria such as Salmonella and Shigella spp., has been identified as the only ligand for TLR5. Both above-mentioned antigens are believed to be dominant antigens in the pathogenesis of human IBD (10, 19). In addition, both were shown to elicit rapid and sustained proinflammatory responses in HIMEC, including upregulation of ICAM-1, as well as increased static and dynamic leukocyte adhesion and enhanced transendothelial leukocyte transmigration (21, 25).
Given that TNF-
is considered one of the most important cytokines driving exaggerated immune responses and anti-TNF-
strategies represent an established treatment in human IBD, we were interested in which genes would be specifically expressed in HIMEC after proinflammatory stimulation with this cytokine. Compared with the microvascular reference endothelial cell line, EBI3 mRNA was markedly enhanced after stimulation with TNF-
(4 h and 24 h, 20 ng/ml) whereas no significant increase in signal was observed in HMEC-1 cells (Table 1). Preincubation with the NF-
B inhibitor MG132 inhibited the upregulation of EBI3 and IL-23p19, but not Il-12p35. These results suggest that expression of specific IL-12-related molecules in HIMEC is dependent on activation of the transcription factor NF-
B. Similar observations have been made for the expression of EBI3 in murine colitis models, where EBI3 expression was tightly dependent on intact NF-
B, as measured by reporter gene constructs (42).
By semiquantitative RT-PCR, we were able to detect stimulated expression of the IL-12-related molecules IL-23p19, IL-12p35, and EBI3 in HIMEC, whereas IL-12p40 and IL-27p28 could not be detected. In contrast, the dermal reference endothelial cell line (HMEC-1) did not show a pronounced response to TNF-
stimulation (Fig. 1). These findings indicate that HMEC-1 as an immortalized cell line may have lost TNF-
sensitivity.
In HIMEC, stimuli generally known to activate the NF-
B pathway appeared to be potent inducers of IL-12-related molecules. Prior data have suggested that upregulation of IL12p40 in endothelial cells is mainly dependent on stimulation with CD154, which is the CD40 ligand (18). In accordance with our data, this group was unable to stimulate IL-12p40 expression in endothelial cells using TNF-
and other stimuli. Our findings leave room for speculation that additional stimuli not yet identified might regulate the expression of these genes in HIMEC. Furthermore, these gene products might be synthesized as monomers, forming IL-12 and IL-23 extracellularly. Interestingly, stimulation of endothelial cells with IFN-
, a proinflammatory stimulus known to utilize the Janus kinase (JAK) as well as signal transducer and activation of transcription (STAT) pathways, did not lead to any regulation of IL-12-related molecules, as assessed by semiquantitative RT-PCR.
There are emerging data supporting a role of endothelial cells in the setting of innate immune responses. Likewise, our group has shown that HIMEC express the PAMP receptors for bacterial LPS and microbial flagellin, TLR4 and TLR5, respectively (21, 25). These data have sparked a hypothesis by which mucosal endothelial cells might be able to sense invading microbia, serving as a second line of mucosal defense (14).
For this reason, we were interested in which PAMP would induce the expression of IL-12-related molecules in HIMEC. Using a variety of well-characterized TLR agonists at established doses, we were intrigued to see that HIMEC appeared to strongly upregulate EBI3 expression after stimulation with the viral antigen analog poly(I:C). As expected, stimulation with the TLR4 agonist LPS and the TLR5 agonist flagellin also appeared to be, to a lesser extent, regulators of this IL-12-related molecule. Using HIMEC stimulated with poly(I:C), we were able to show upregulation of EBI3 on the protein level, as assessed by immunoblotting using the monoclonal antibody specific for EBI3 (8). Expression of EBI3 was further assessed by indirect immunofluorescence, where HIMEC stimulated with poly(I:C) showed a striking increase in cytosolic EBI3 immunoreactivity.
Having learned that the TLR3 agonist poly(I:C) appears to be a regulator of specific IL-12-related molecules in HIMEC, we were interested in whether HIMEC would express TLR3. As expected, HIMEC displayed both constitutive and regulated expression of TLR3, as assessed by semiquantitative RT-PCR. These findings were further corroborated by flow cytometry and immunofluorescence experiments from which we learned that endothelial expression of TLR3 is potently controlled by the ligand poly(I:C) itself.
According to what is known about the differentiation of naive CD4+ T cells, IL-12-related cytokines such as IL-17, IL-23, and IL-27 appear to act in a sequential and time-dependent manner (6) to induce Th1, Th2, and TH17 differentiation in naive CD4+ T cells (Th0 cells) (16). Using quantitative real-time RT-PCR, we assessed the time course of IL-12-related molecule expression in HIMEC in response to continuous stimulation with a fixed dose of poly(I:C). Interestingly, IL-23p19 was upregulated as early as 2 h after stimulation, whereas EBI3 expression levels peaked at later time points. These findings may reflect sequential innate immune functions elicited by mucosal endothelial cells upon activation of TLR3 by viral antigens.
IL-12 was found to be expressed at high levels in actively inflamed mucosa of both CD and UC (24). A recent study published by Stallmach et al. (37) was suggestive of a therapeutic effect of the IL-12p40-IgG2b dimeric fusion protein in experimental murine colitis models.
IL-23 is a heterodimer of the subunit p19, which is structurally related to IL-12p35, and IL-12p40. In contrast to IL-12, IL-23 was found to stimulate the proliferation of memory (CD4+CD45RB low) T cells (27). Recently, IL-23 was shown to stimulate differentiation of naive T cells into a novel subset of T cells termed Th17 or Th IL-17 cells. Th17 cells, which represent a major source of IL-17 upon stimulation with IL-23, are believed to exert proinflammatory effects of secondary local cell populations, including macrophages/monocytes and fibroblasts as well as endothelial cells. In these cells, IL-17 derived from Th17 cells is believed to set off a paracrine and autocrine secretion of proinflammatory effector mediators, including IL-1, IL-6, IL-8, and TNF-
.
The crucial proinflammatory role of IL-23 is evident, because mice ubiquitously overexpressing the IL-23 subunit p19 were found to suffer from generalized and lethal inflammatory disease (41). Current knowledge suggests constitutive expression of IL-23 in dendritic cells in the terminal ileum of mice (3).
Recent data have shown a beneficial effect brought about by neutralization of IL-23 biological activity rather than of IL-12 in experimental models of murine IBD (43). In these experimental series, antibody treatment neutralizing the biological activity of anti-IL-23p19 was superior to anti-p40 (subunit of both IL-12 and IL-23) in preventing the onset of and treating established murine experimental colitis (43). These findings are suggestive of a previously underestimated role of IL-23 in regulating intestinal inflammation. Interestingly, a new study supports a role of distinct IL23R mutations as a predisposing factor in the development of IBD (9).
The role of IL-27 in IBD remains to be identified as of yet. In vitro studies have shown a marked upregulation of IL-27 in activated monocytes and dendritic cells, which led to the idea that antigen-presenting cells might represent the main source of secreted IL-27 in vivo. However, biological functions of IL-27 are poorly understood. IL-27 was found to specifically bind to the receptor T cell cytokine receptor (TCCR) [synonomous with WSXWS type I receptor (WSX-1)], which is highly expressed by naive T cells (30). IL-27 induces the proliferation of CD4+ naive T cells and acts synergistically with IL-12 to induce expression of IFN-
(30). In addition, IL-27 appears to play an important role in the regulation of Th1-mediated immune responses (31). Microvascular endothelial cells derived from human gut (HIMEC) were demonstrated to possess antigen-presenting functions in vivo (12).
In conclusion, regulated production of IL-12-related molecules by mucosal endothelial cells might reflect adaptive immune functions in response to specific microbial antigens translocated into deeper mucosal layers. These immune functions may involve both secreted factors and direct interactions between mucosal endothelial cells and circulating and tissue-bound mononuclear cells.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W. G. Cho, R. J. C. Albuquerque, M. E. Kleinman, V. Tarallo, A. Greco, M. Nozaki, M. G. Green, J. Z. Baffi, B. K. Ambati, M. De Falco, et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth PNAS, April 28, 2009; 106(17): 7137 - 7142. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |